http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
IMV Inc. (IMV) Announces Chief Financial Officer to Retire
-
IMV Inc. Announces Chief Financial Officer to Retire
-
IMV Inc. Announces Third Quarter 2021 Financial and Operational Update
-
Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
-
IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021
-
Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
-
Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
-
IMV’s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
-
IMV Inc. to Present at Three Investor Conferences in September
-
IMV Inc. Announces Second Quarter 2021 Financial and Operational Results
-
IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer
-
IMV Announces CEO Transition
-
IMV Inc. to Announce Second Quarter 2021 Results and Host a Conference Call and Webcast on August 11, 2021
-
IMV to Participate in the BTIG Virtual Biotechnology Conference
-
IMV Announces Annual and Special Meeting of Shareholders Voting Results
-
IMV Announces Appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer And Addition of Clinical Advisor
-
Independent Proxy Advisory Firms Recommend IMV Shareholders Vote for All Director Nominees at the Upcoming Annual General and Special Meeting
-
IMV Inc. to Present at Two Upcoming Investor Conferences
-
IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline
-
IMV Inc. (IMV) Announces Dr. Michael Kalos to Board
-
IMV Appoints Dr. Michael Kalos to Board of Directors
-
IMV’s Lead Immunotherapy to be Investigated in Breast Cancer
-
IMV Inc. to Announce First Quarter 2021 Results and Host a Conference Call and Webcast on May 12, 2021
-
IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference
-
IMV Inc. (IMV) Announces Company-Sponsored Clinical Trial in Patients with r/rDLBCL in Collaboration with Merck (MRK) Following Feedback from FDA
-
IMV Announces Company-Sponsored Clinical Trial in Patients with r/rDLBCL in Collaboration with Merck Following Feedback from FDA
-
IMV Inc. (IMV) Names Kyle Kuvalanka to Board
-
IMV Appoints Kyle Kuvalanka to Board of Directors
-
IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results
-
IMV to Announce Fourth Quarter and Fiscal 2020 Financial and Operational Results and Host Conference Call and Webcast on March 17, 2021
-
IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference
-
IMV to Participate in Two Upcoming Investor Events
-
IMV Inc. (IMV) Provides Update on COVID-19 Vaccine Program, Says 'Encouraged' by Data Thus Far
-
IMV Reports Update on COVID-19 Vaccine Program
-
Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting
-
IMV Inc. (IMV) Announces Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer
-
IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer
-
IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy
-
IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update
-
IMV Strengthens Leadership Team with Appointment of Andrew Hall as Chief Business Officer
-
IMV to Participate in Two Upcoming Investor Conferences
-
IMV's T (IMV) Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck’s Keytruda® in PD-L1 Positive Patients with r/r DLBCL
-
IMV’s T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck’s Keytruda® in PD-L1 Positive Patients with r/r DLBCL
-
Updated Clinical Data From Phase 2 SPiReL Study Evaluating IMV’s T Cell Therapy in Combination With Merck’s Keytruda® in Patients With r/r DLBCL to Be Presented at The American Society of Hematol
-
IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers Associated With Clinical Response in Patients With r/r DLBCL treated with DPX-Survivac Combination Therapy
-
Biomarkers Associated With Clinical Response in Patients With r/r DLBCL Treated With DPX-Survivac Combination Therapy to be Presented at the Upcoming SITC Annual Meeting
-
IMV Inc. (IMV) Provides Updates On COVID-19 Vaccine Program
-
IMV Provides Updates On COVID-19 Vaccine Program
-
IMV CEO to Participate at the Vaccines Panel of the Sachs Associates 20th Annual Biotech in Europe Forum
-
IMV to Participate at Four Upcoming Investor Conferences
